Business
J&J Bets Up to $2.6B on Sail’s ‘In Vivo’ CAR-T for Autoimmune Disease
Johnson & Johnson pays $785 million upfront for an option to buy Flagship-backed Sail Biomedicines, whose nanoparticle-and-RNA platform aims to make CAR-T inside the body.